市場調查報告書
商品編碼
925305

器官移植免疫抑制劑市場:成長,趨勢,預測(2020年∼2025年)

Organ Transplant Immunosuppressant Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 100 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

器官移植免疫抑製藥市場在預測期間內預計將以3.5%的年複合成長率成長。免疫抑制劑和抗排斥藥,是降低拒絕移植的內臟器官的身體能力的藥的種類。免疫抑制劑有引進劑和維持劑2種,導入劑與長期性地使用的維持劑。根據世界衛生組織(WHO),在世界每年約有10萬800件固態器官移植進行,其中腎臟移植6萬9,400件,肝臟移植2萬200件,心臟移植5,400件,肺移植3,400件,胰臟移植2,400件。慢性疾病的發病率增加,組織工程和器官移植的技術進步,成為帶動器官移植免疫抑制劑市場的主要原因。

本報告提供器官移植免疫抑製藥市場調查,市場概要,各市場成長要素及阻礙因素分析,各藥物類別、各移植類型、各地區的市場規模的變化與預測,競爭情形,主要企業的簡介,市場機會等全面性資訊。

目錄<

第1章 簡介

  • 調查的前提條件
  • 調查範圍

第2章 調查手法

第3章 摘要整理

第4章 市場動態

  • 市場概要
  • 市場成長要素
    • 慢性疾病的發生率的上升增加移植的需求
    • 組織工程和器官移植的技術進步
  • 市場阻礙因素
    • 移植的高成本
    • 內臟器官的可用性低
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 競爭加劇

第5章 市場細分化

  • 各藥物類別
    • Calcineurin抑制劑
    • 抗增生劑
    • mTOR抑制劑
    • 類固醇
    • 其他藥物類別
  • 各移植類型
    • 心臟
    • 腎臟
    • 肝臟
    • 胰臟
    • 其他移植類型
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲地區
    • 南美

第6章 競爭情形

  • 企業簡介
    • Astellas Pharma, Inc
    • Sanofi (Genzyme)
    • Bristol-Myers Squibb Company
    • Novartis AG
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline Plc
    • Accord Healthcare Ltd
    • Mylan Laboratories, Inc
    • Dr. Reddy's Laboratories Ltd
    • Veloxis Pharmaceuticals A/S

第7章 市場機會及未來趨勢

目錄
Product Code: 67838

The Organ Transplant Immunosuppressant Drugs Market is expected to register a CAGR of 3.5% during the forecast period. Organ transplantation is a medical procedure used to replace a damaged or missing organ by removing it from the donor and placing in the body of the recipient and this can be done either when the donor and the recipient are at the same location or the organs are transported from the donor location to the recipient. Organs such as kidneys, liver, heart, lungs, pancreas, etc. can be successfully transplanted, and among them, kidney transplants are the most common, followed by liver transplants and then heart transplants.

Immunosuppressants or anti-rejection drugs are the categories of drugs that lower the body's ability to reject a transplanted organ. There are two types of immunosuppressants drugs, induction and maintenance drugs, induction drugs used at the time of transplant and maintenance drugs used for the long term. According to the World Health Organization (WHO), approximately 100,800 solid organ transplants are performed every year worldwide among them 69,400 kidney transplants, 20,200 liver transplants, 5,400 heart transplants, 3,400 lung transplants, and 2,400 pancreas transplants. Increasing the incidence of chronic ailments and technological advancements in tissue engineering and organ transplantations are the key driving factors in the organ transplant immunosuppressant drugs market.

Key Market Trends

Calcineurin Inhibitors Segment is Expected to Hold a Major Market Share in the Organ Transplant Immunosuppressant Drugs Market

  • Calcineurin inhibitors are medicines that inhibit the action of calcineurin which is an enzyme that activates T-cells of the immune system. These inhibitors exert their effects by reducing interleukin-2 production and receptor expression, leading to a reduction in T-cell activation.
  • According to the U.S. Department of Health and Human Services and Health Resources and Services Administration, more than 113,000 people were in need of transplants as of 2019 and 36,528 transplants were performed in the year 2018.
  • Calcineurin Inhibitors segment holds a significant market share in the organ transplant immunosuppressant drugs market and is anticipated to show a similar trend over the forecast period due to effective and have been used in kidney transplant recipients for a long period, even though they hold extensive toxicity profile.
  • Rising incidence of kidney failures which increases the demand for kidney transplantation and technological advancements in organ transplantations are the key driving factors in the calcineurin inhibitors segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global organ transplant immunosuppressant drugs market due to the high number of transplant procedures, increasing incidence of chronic ailments and the presence of favorable reimbursement policies in this region. According to the Disease Control and Prevention (CDC), the most commonly transplanted organs in the United States are kidney, liver, heart, lungs, pancreas, and intestine. A total number of transplant procedures is dependent on the number of donors, as on an average every day, there are about 75,000 people on the active waiting list for organ transplantation. Furthermore, technological advancements in tissue engineering and organ transplantations, increasing healthcare spending and the presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Organ Transplant Immunosuppressant Drugs Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Astellas Pharma, Inc, Sanofi (Genzyme), Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Accord Healthcare Ltd, Mylan Laboratories, Inc, Dr. Reddy's Laboratories Ltd and Veloxis Pharmaceuticals A/S.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence of Chronic Ailments Increases Demand for Transplantations
    • 4.2.2 Technological Advancements in Tissue Engineering and Organ Transplantations
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Transplantation
    • 4.3.2 Low Availability of Organs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Calcineurin Inhibitors
    • 5.1.2 Antiproliferative Agents
    • 5.1.3 mTOR Inhibitor
    • 5.1.4 Steroids
    • 5.1.5 Others Drug Class
  • 5.2 By Transplant Type
    • 5.2.1 Heart
    • 5.2.2 Kidney
    • 5.2.3 Liver
    • 5.2.4 Lung
    • 5.2.5 Pancreas
    • 5.2.6 Other Transplant Type
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Astellas Pharma, Inc
    • 6.1.2 Sanofi (Genzyme)
    • 6.1.3 Bristol-Myers Squibb Company
    • 6.1.4 Novartis AG
    • 6.1.5 F. Hoffmann-La Roche Ltd
    • 6.1.6 GlaxoSmithKline Plc
    • 6.1.7 Accord Healthcare Ltd
    • 6.1.8 Mylan Laboratories, Inc
    • 6.1.9 Dr. Reddy's Laboratories Ltd
    • 6.1.10 Veloxis Pharmaceuticals A/S

7 MARKET OPPORTUNITIES AND FUTURE TRENDS